Clinical trials: Moderate-to-severe Psoriasis
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER II (NCT01468233)
- Testing
- adalimumab
- Volunteers
- 326 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis
CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira® when used in patients with…
- Trial name
- CALYPSO (NCT02762955)
- Testing
- BCD-057, Humira®
- Where
- Russia
- Volunteers
- 344 people
- Sponsor
- Biocad
Plaque Psoriasis
A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of multiple-dose HSK47388 versus placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07158268
- Testing
- HSK47388
- Volunteers
- 220 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Plaque Psoriasis
A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of AIN457 to placebo.
- Trial name
- NCT00669916
- Testing
- AIN457
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03875482
- Testing
- Risankizumab
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 157 people
- Sponsor
- AbbVie
Plaque Psoriasis
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.
- Trial name
- ObePso-S (NCT03055494)
- Testing
- Secukinumab
- Where
- 15 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01937260
- Testing
- Brodalumab
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 31 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- OptIMMize-2 (NCT04862286)
- Testing
- Risankizumab
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 132 people
- Sponsor
- AbbVie
Psoriasis
Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
W11-050 is a Mexican open label multicenter study that has been designed to further assess the safety and efficacy of adalimumab in the treatment of patients with active plaque psoriasis who have failed prior conventional…
- Trial name
- NCT01265823
- Testing
- Adalimumab
- Where
- 8 sites in Mexico
- Volunteers
- 150 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis
The purpose of this study is to assess the safety, tolerability, immunogenicity, and clinical effects of AMG 811 following single subcutaneous dose administration in subjects with moderate to severe psoriasis.
- Trial name
- NCT01510951
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 9 people
- Sponsor
- Amgen
Plaque Psoriasis
Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis
This is an open-label Phase III clinical study to evaluate the long-term safety and efficacy of AK101 injection in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05509361
- Testing
- AK101 injection SC
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Akeso
Psoriasis
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
To assess long-term safety, tolerability, and efficacy of BI 730357 in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03835481
- Testing
- BI 730357
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 165 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
- Trial name
- NCT02933528
- Testing
- DSXS Topical product
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Plaque Psoriasis
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by…
- Trial name
- STEPin (NCT03020199)
- Testing
- Secukinumab, nb-UVB
- Where
- 44 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 196 people
- Sponsor
- Novartis Pharmaceuticals
Generalized Pustular Psoriasis (GPP)
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute…
- Trial name
- NCT06231381
- Testing
- HB0034
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Plaque Psoriasis
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from…
- Trial name
- NCT04102007
- Testing
- Risankizumab
- Where
- 57 sites in United States, Australia and 6 more
- Volunteers
- 244 people
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
Raptiva in Palm and Sole Psoriasis
The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or soles scoring Palmo-plantar Pustular…
- Trial name
- NCT00972543
- Testing
- Efalizumab (Raptiva)
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection…
- Trial name
- NCT03766685
- Testing
- Bimekizumab
- Where
- 39 sites in United States, Canada
- Volunteers
- 172 people
- Sponsor
- UCB Biopharma SRL